Search
Bucindolol
go.drugbank.com/drugs/DB12752InvestigationalBucindolol has been investigated in Heart Failure.
Categories: Cytochrome P-450 Substrates, Adrenergic alpha-1 Receptor AntagonistsTAK-901
go.drugbank.com/drugs/DB12756InvestigationalTAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingOpaganib
go.drugbank.com/drugs/DB12764InvestigationalOpaganib, also known as ABC294640, is a selective [sphingosine kinase-2 (SK2)](https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 4-Pyridinylmethyl 3(4-Chlorophenyl)Adamantine Carboxamide, 4-Pyridinylmethyl-3-(4-Chlorophenyl) Adamantine CarboxamideVeldoreotide
go.drugbank.com/drugs/DB12777InvestigationalSomatoprim is under investigation for the treatment of Acromegaly.
Higenamine
go.drugbank.com/drugs/DB12779InvestigationalHigenamine is under investigation in clinical trial NCT01451229 (Pharmacokinetics and Pharmacodynamics of Higenamine in Chinese Healthy Subjects).
Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household settingNorethandrolone
go.drugbank.com/drugs/DB12787InvestigationalNorethandrolone is under investigation in clinical trial NCT00700544 (Treatment Outcome in Elderly Patients).
Dinoprost
go.drugbank.com/drugs/DB12789ApprovedWithdrawnDinoprost has been investigated in Headache.
Categories: Prostaglandins FDaniquidone
go.drugbank.com/drugs/DB12804InvestigationalDaniquidone has been used in trials studying the treatment of Neoplasms.
Categories: Heterocyclic Compounds, 2-RingZoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigational[A274938,L54748] It is indicated as a single-dose oral therapy for the treatment of uncomplicated urogenital gonorrhea. … [A275268] Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), thereby blocking
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesConcizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigationalConcizumab is a humanized IgG4 monoclonal antibody targeting the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), a key regulator of the coagulation cascade. … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.